Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.597
+0.025 (4.43%)
At close: Apr 28, 2026, 4:00 PM EDT
0.589
-0.008 (-1.27%)
After-hours: Apr 28, 2026, 7:54 PM EDT
Vistagen Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Vistagen Therapeutics stock has a target of 0.90, which predicts an increase of 50.85% from the current stock price of 0.60.
Analyst Consensus: Hold
* Price targets were last updated on Dec 17, 2025.
Analyst Ratings
The average analyst rating for Vistagen Therapeutics stock from 3 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Dec 17, 2025 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 17, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $15 → $0.9 | Strong Buy → Hold | Downgrades | $15 → $0.9 | +50.85% | Dec 17, 2025 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $0.2 → $15 | Hold → Strong Buy | Upgrades | $0.2 → $15 | +2,414.25% | Dec 7, 2023 |
| Stifel | Stifel | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +1,911.40% | Nov 14, 2023 |
Financial Forecast
Revenue This Year
1.09M
from 486.00K
Increased by 124.49%
Revenue Next Year
4.95M
from 1.09M
Increased by 353.99%
EPS This Year
-1.82
from -1.67
EPS Next Year
-1.12
from -1.82
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.4M | 8.9M | ||||||
| Avg | 1.1M | 5.0M | ||||||
| Low | 784,000 | 1.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 180.9% | 718.1% | ||||||
| Avg | 124.5% | 354.0% | ||||||
| Low | 61.3% | 8.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.67 | -0.71 | ||||||
| Avg | -1.82 | -1.12 | ||||||
| Low | -1.89 | -1.39 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.